Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

In this study, oral spermidine supplementation was found to significantly prolong the hair follicle anagen phase and reduce hair loss, with effects persisting three months after treatment in healthy participants, suggesting potential therapeutic benefits for hair loss conditions.

Botulinum toxin may help treat male pattern baldness.

In this study, microneedle combined with 5% topical minoxidil significantly increased hair count in androgenetic alopecia, suggesting it as a potential additional therapy option; however, microneedle alone had limited effects.

This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.

This study reported that seed germination and root hair growth were significantly enhanced after exposure to an individual whose depression was treated with Emotional Freedom Techniques, suggesting that human mood may influence seed viability.

In this study, both resistance training and aerobic exercise with lifestyle modification were similarly effective for managing PCOS symptoms, but resistance training showed more significant benefits for BMI and menstrual regularity.

This study found that acupressure on specific points improved health-related quality of life and reduced total testosterone levels and clinical symptoms in patients with polycystic ovary syndrome compared to controls.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after six months, compared to those containing levonorgestrel.

This study found that oral minoxidil 1 mg daily was as effective and safe as topical minoxidil 5% solution for treating female pattern hair loss over 24 weeks, but more likely to cause excessive hair growth elsewhere.

This study found that vitamin D supplementation increased the cumulative ovulation rate in vitamin D deficient women with polycystic ovary syndrome compared to those with normal vitamin D levels and a control group.

This study found that six months of using 0.5% finasteride cream did not significantly reduce hair number or thickness in women with idiopathic facial hirsutism, though patients perceived less hair growth.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

This study found that combining minoxidil with platelet-rich plasma and basic fibroblast growth factor was the most effective treatment for increasing hair density in androgenetic alopecia, showing a significant improvement over minoxidil alone.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

In this meta-analysis, researchers found that oral and topical minoxidil treatments for androgenetic alopecia had similar efficacy in improving hair density and diameter, but oral minoxidil resulted in a higher incidence of hypertrichosis compared to topical use.

This review discusses the impact of 5α-reductase inhibitors on sexual function and presents results from a meta-analysis of randomized controlled trials, without reporting new clinical findings.

This study suggests that a proprietary nutraceutical supplement gummy and peptide serum regimen may be safe and effective for improving hair growth and density in females with pattern hair loss.

This study found that platelet-rich plasma therapy led to significantly increased hair growth and density compared to placebo in patients with androgenic alopecia over six months.

In this study, both platelet-rich plasma and minoxidil increased hair counts and density in moderate androgenetic alopecia in men, but patient satisfaction was higher with minoxidil, which also had fewer side effects.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This study found that SER120 nasal spray significantly improved nocturia symptoms and quality of life compared to placebo in patients 50 years and older, with both tested doses showing efficacy and an acceptable safety profile over a 12-week period.

This study concluded that a regimen containing functional antioxidants and barrier-enhancing agents reduced hair shedding and increased perceived hair fullness in participants with self-perceived hair thinning over 24 weeks.

This study found that applying a 1% BOI lotion improved hair density and thickness in patients with mild pattern hair loss over six months.

In this study, adults with mild-to-moderate hair damage taking GPVGPS Collagen® daily for 24 weeks showed significant improvements in hair luster, strength, thickness, and density compared to placebo, with no safety concerns reported.

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

This study suggests that a turpentine ointment may be an effective and safe treatment for acute folliculitis, as it showed improvements over placebo in lesion evolution, responder rate, and patient assessments.